English, Article edition: Economics of the Antithymocyte Globulins Thymoglobulin(R) and Atgam(R) in the Treatment of Acute Renal Transplant Rejection Mark A. Schnitzler; Robert S. Woodward; Jeffrey A. Lowell; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119454
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economics of the Antithymocyte Globulins Thymoglobulin(R) and Atgam(R) in the Treatment of Acute Renal Transplant Rejection
Author
  • Mark A. Schnitzler
  • Robert S. Woodward
  • Jeffrey A. Lowell
  • Leah Amir
  • Timothy J. Schroeder
  • Gary G. Singer
  • Daniel C. Brennan
Physical Description
  • article
Notes
  • Objective: To evaluate the economic implications for transplant centres, Medicare and society of treatment of corticosteroid-resistant Banff Grades I, II and III acute kidney transplant rejection with the antithymocyte globulins Thymoglobulin(R) or Atgam(R). Design and setting: This was a cost analysis of a randomised double-blind multicentre clinical trial comparing the safety and efficacy of Thymoglobulin(R) and Atgam(R) that was performed at 25 centres in the US in 1994 to 1996. Patients and participants: The study enrolled 163 patients, 82 in the Thymoglobulin(R) arm and 81 in the Atgam(R) arm. Methods: Estimates of the cost of care from the initiation of rejection therapy to 90 days post-therapy were derived from various publicly available sources and applied to patient-specific clinical events documented in the clinical trial. Patients received either intravenous Thymoglobulin(R) (1.5 mg/​kg/​day) for an average of 10 days or intravenous Atgam(R) (15 mg/​kg/​day) for an average of 9.7 days. Results: On average, Thymoglobulin(R) provided significant cost savings compared with Atgam(R) from the perspective of society [$US5977 (1996 values); 95% confidence interval (CI) $US3719 to $US8254], Medicare ($US4967; 95% CI $US3256 to $US6678) and the transplant centre ($US3087; 95% CI $US1512 to $US4667). The overall advantage attributable to Thymoglobulin(R) was primarily due to savings from fewer recurrent rejection treatments and less frequent return to dialysis. Conclusions: Treatment of acute renal transplant rejection with Thymoglobulin(R) is a cost saving strategy when compared with treatment with Atgam(R).
  • Antithymocyte globulin Merieux, Antithymocyte globulin Upjohn, Cost analysis, Immunomodulators, Pharmacoeconomics, Renal transplant rejection
  • RePEc:wkh:phecon:v:17:y:2000:i:3:p:287-293
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment